The integration of deuterium into pharmaceutical compounds, referred to as deuteration, constitutes a transformative approach within the field of medicinal chemistry, possessing the capacity to fundamentally alter the therapeutic landscape for leukemia treatment. Deuterium, a stable and non-radioactive isotope of hydrogen, when introduced into pharmaceutical entities, has the potential to markedly improve their metabolic stability and pharmacokinetic characteristics. This modification has the potential to yield extended pharmacological action, diminished toxicity, and enhanced therapeutic efficacy, thereby addressing several significant challenges that are prevalent in contemporary leukemia treatment modalities.